The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma

Journal of Pathology

Volumn 208, Issue 3, 2006, Pages 431-438

  Khnykin, Denis ^a   Troen, Gunhild ^a   Berner, Jeanne Marie ^a   Delabie, Jan ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Fibroblast growth factor; Fibroblast growth factor receptor; Hodgkin's lymphoma; Lymphoma

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOMA CELL LINE; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

CELL HYPOXIA; CELL LINE, TUMOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HODGKIN DISEASE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, FIBROBLAST GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 32244441965     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1900     Document Type: Article

References (34)

1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:reviews 3005.1-3005.12.
2. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-197.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
4. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-178.
5. Mugneret F, Chaffanet M, Maynadie M, Guasch G, Favre B, Casasnovas O et al. The 8p12 myeloproliferative disorder t(8;19)(p12;q13.3): a novel translocation involving the FGFR1 gene. Br J Haematol 2000;111:647-649.
6. Moroni E, Dell'Era P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in haematopoiesis and hematological tumors. J Hematother Stem Cell Res 2002;11:19-32.
7. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-264.
8. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997;90:4062-4070.
9. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukaemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
10. Krejci P, Faitova J, Laurell H, Hampl A, Dvorak P. FGF-2 expression and its action in human leukaemia and lymphoma cell lines. Leukaemia 2003;17:818-820.
11. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999;94:3334-3339.
12. Ho CL, Shen LF, Li CY. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin's lymphoma. Appl Immunohistochem Mol Morphol 2002;10:316-321.
13. Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M et al. Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Cancer 2002;86:1770-1775.
14. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leukocyte Res 2004;28:595-604.
15. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol 2004;5:19-26.
16. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M et al. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J 1990;9:2685-2692.
17. Partanen J, Makela TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L et al. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 1991;10:1347-1354.
18. Crumley G, Bellot F, Kaplow JM, Schlessinger J, Jaye M, Dionne CA. High-affinity binding and activation of a truncated FGF receptor by both aFGF and bFGF. Oncogene 1991;6:2255-2262.
19. Keegan K, Meyer S, Hayman MJ. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 1991;6:2229-2236.
20. Chin SF, Daigo Y, Huang HE, Iyer NG, Callagy G, Kranjac T et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridization on tissue microarrays of paraffin wax-embedded tumour samples. Mol Pathol 2003;56:275-279.
21. Doussis-Anagnostopoulou IA, Talks KL, Turley H, Debnam P, Tan DC, Mariatos G et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin's-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002;197:677-683.
22. Finelli P, Fabris S, Zagano S, Baldini L, Intini D, Nobili L et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Blood 1999;94:724-732.
23. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma - molecular biology of Hodgkin's and Reed-Sternberg cells. Lancet Oncol 2004;5:11-18.
24. Ohshima K, Sugihara M, Suzumiya J, Haraoka S, Kanda M, Shimazaki K et al. Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Pathol Res Pract 1999;195:149-155.
25. Johnston CL, Cox HC, Gomm JJ, Coombes RC. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments - a splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 1995;270:30643-30650.
26. Maher PA. Nuclear translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol 1996;134:529-536.
27. Reilly JF, Maher PA. Importin β-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J Cell Biol 2001;152:1307-1312.
28. Peng H, Moffett J, Myers J, Fang X, Stachowiak EK, Maher P et al. Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell 2001;12:449-462.
29. Olsnes S, Klingenberg O, Wiedlocha A. Transport of exogenous growth factors and cytokines to the cytosol and to the nucleus. Physiol Rev 2003;83:163-182.
30. Johnson HM, Subramaniam PS, Olsnes S, Jans DA. Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. BioEssays 2004;26:993-1004.
31. Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-Subero JI et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003;103:489-495.
32. Wilkie AOM. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 2005;16:187-203.
33. Cappellen D, De OC, Ricol D, De MS, Bourdin J, Sastre-Garau X et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
34. Logie A, Dunois-Larde C, Rosty C, Levrel O, Blanche M, Ribeiro A et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005;14:1153-1160.